| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2022 | Nirogi R, Ieni J, Goyal VK, Ravula J, Jetta S, Shinde A, Jayarajan P, Benade V, Palacharla VRC, Dogiparti DK, Jasti V, Atri A, Cummings J. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. Alzheimer's & Dementia (New York, N. Y.). 8: e12307. PMID 35662833 DOI: 10.1002/trc2.12307 | 0.353 | |||
| 2008 | Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs & Aging. 25: 163-74. PMID 18257603 DOI: 10.2165/00002512-200825020-00008 | 0.355 | |||
| 2005 | Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry. 20: 559-69. PMID 15920715 DOI: 10.1002/Gps.1325 | 0.424 | |||
| 2003 | Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry. 160: 2003-11. PMID 14594748 DOI: 10.1176/Appi.Ajp.160.11.2003 | 0.356 | |||
| 2003 | Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society. 51: 937-44. PMID 12834513 DOI: 10.1046/J.1365-2389.2003.51306.X | 0.411 | |||
| 2003 | Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM. Donepezil HCl (E2020) Maintains Functional Brain Activity in Patients With Alzheimer Disease: Results of a 24-Week, Double-Blind, Placebo-Controlled Study American Journal of Geriatric Psychiatry. 11: 169-177. DOI: 10.1097/00019442-200303000-00007 | 0.317 | |||
| 2003 | Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni J, Schwam E. P.4.040 Donepezil has significant functional and behavioral benefits in patients with severe Alzheimer's disease European Neuropsychopharmacology. 13. DOI: 10.1016/S0924-977X(03)92234-6 | 0.345 | |||
| 2002 | Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. International Journal of Clinical Practice. 56: 441-6. PMID 12166542 | 0.338 | |||
| 2001 | Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 57: 481-8. PMID 11502917 DOI: 10.1212/Wnl.57.3.481 | 0.374 | |||
| 2001 | Provenzano G, Duttagupta S, McRae T, Mastey V, Ellis B, Ieni J. Ppn13: Delays In Nursing Home Placement For Patients With Alzheimer'S Disease Associated With Treatment With Donepezil May Have Health Care Cost-Saving Implications Value in Health. 4: 158. DOI: 10.1046/J.1524-4733.2001.40202-235.X | 0.37 | |||
| 2000 | Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 10: 195-203. PMID 10793322 DOI: 10.1016/S0924-977X(00)00067-5 | 0.422 | |||
| 1999 | Ieni JR, Perdomo CA, Pratt RD. Safety of donepezil in extended treatment of Alzheimer's disease European Neuropsychopharmacology. 9: 328-329. DOI: 10.1016/S0924-977X(99)80461-1 | 0.333 | |||
| 1999 | Mohs R, Doody R, Morris J, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year prospective placebo-controlled attrition study European Neuropsychopharmacology. 9: 328. DOI: 10.1016/S0924-977X(99)80460-X | 0.382 | |||
| Show low-probability matches. | |||||